ClinicalTrials.gg
CompletedNCT00249249Updated Jan 12, 2010Results posted

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

A Phase 3 interventional study of Pitavastatin and Atorvastatin in Primary Hypercholesterolemia and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 192 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-01-12.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
830
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
4th of 19
830 · median 200
Started
2005
with 4 others
Phase 3
9 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
7 of 19
Kowa Research Europe

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 4th largest by enrollment, is one of 5 that started in 2005, is one of 9 in phase 3, and was the 2nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin.

Read the detailed description

Following a wash-out dietary lead-in period, patients will receive either Atorvastatin or Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing cholesterol levels.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Dyslipidemia

Browse trials for

Keywords

  • hypercholesterolemia
  • dyslipidemia
  • kowa
  • KRE
  • pitavastatin
  • NK-104
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 830 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females (age 18-75 years).
  • Non-pregnant, non-lactating females
  • Women of child bearing potential should use sustained preparations or an approved mechanical contraceptive method.
  • Eligible and able to participate and have given
  • Must have been following a restrictive diet and does not eat or drink grapefruit
  • Diagnosis of primary hypercholesterolemia or combined dyslipidemia
  • Available for every clinic visit, which will occur in the morning.

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia
  • Conditions which may cause secondary dyslipidemia.
  • Condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
  • History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury
  • Liver injury
  • Impaired renal function
  • Current obstruction of the urinary tract or difficulty in voiding due to mechanical as well as inflammatory conditions, which is likely to require intervention during the course of the study or is regarded as by the investigator
  • Serum creatine kinase (CK) >5 x upper limit of the reference range (ULRR).
  • Uncontrolled hypothyroidism
  • Severe acute illness or severe trauma in the last 3 months
  • Major surgery, 3 months prior to Visit 1
  • Significant cardiovascular disease (CVD) prior to randomization
  • Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response rate of >100 beats per minute at rest.
  • Left ventricular (LV) \< 0.25
  • History of symptomatic cerebrovascular disease
  • Conditions at the discretion of the investigator
  • Known infection
  • Poorly controlled or uncontrolled hypertension.
  • Known muscular or neuromuscular disease of any type
  • Neoplastic disease
  • Drug abuse or continuous consumption of more than 65 mL pure alcohol per day
  • Exposure to any new drug within 30 days of study entry or ingestion of any drug known to be toxic to a major organ system
  • Current or recent use of supplements known to alter lipid metabolism
  • reactions to other HMG-CoA reductase inhibitors
  • Concomitant medication not permitted
  • Resistant to lipid-lowering medications. Known hypersensitivity or intolerance to any lipid lowering agent
  • Excessive obesity
  • Regular clinic attendance in the morning impractical
  • Signs of mental dysfunction or other factors likely to limit ability to cooperate
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
830 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Percent Change From Baseline in Total Cholesterol (TC)

    Percent change in total cholesterol from baseline to Week 12

    Time frame: Baseline to 12 Weeks

  2. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)

    percent change from baseline in high density lipoprotein-cholesterol (HDL-C)

    Time frame: Baseline to 12 weeks

  3. TC:HDL-C Ratio

    Ratio of mean total cholesterol to mean HDL-C at 12 weeks

    Time frame: 12 weeks

  4. Triglycerides (TG)

    mean triglycerides at 12 weeks

    Time frame: 12 weeks

  5. Non-HDL:HDL Ratio

    Ratio of non-HDL to HDL at 12 weeks

    Time frame: 12 weeks

  6. Apolipoprotein B (Apo B)

    Apolipoprotein B at 12 weeks

    Time frame: 12 weeks

  7. Apolipoprotein-A1 (Apo-A1)

    Apolipoprotein-A1 at 12 weeks

    Time frame: 12 weeks

  8. Apo-B:Apo-A1 Ratio

    Ratio of Apo-B to Apo-A1 at 12 weeks

    Time frame: 12 weeks

  9. High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks

    high sensitivity C-reactive protein (hs-CRP) at 12 weeks

    Time frame: 12 weeks

  10. Oxidized LDL at 12 Weeks

    oxidized low density lipoprotein at 12 weeks

    Time frame: 12 weeks

  11. National Cholesterol Education Program [NCEP]LDL-C Target Attainment

    Number of patients achieving NCEP LDL-C target (LDL-C less than or equal to 130 mg/dL)

    Time frame: up to 12 weeks

08

Results

Posted Dec 16, 2009

Participant flow

First Patient In: 4 October 2005 Last Patient Out: 8 November 2006 A total of 39 investigators at 39 sites in India, Russia, Spain and Denmark received IRB approval to participate in this study and screened and randomized patients.

Participant flow — Overall Study
MilestonePitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Started321103303103
Safety population316102300103
Completed30198288100
Not completed205153

Outcome measures

PrimaryPercent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12
Time frame:
Baseline to 12 weeks
Reported as:
Mean · percent change
Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12
percent changePitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12-37.89 ± 13.841-38.76 ± 14.582-45.5 ± 14.005-43.9 ± 15.853
SecondaryPercent Change From Baseline in Total Cholesterol (TC)

Percent change in total cholesterol from baseline to Week 12

Time frame:
Baseline to 12 Weeks
Reported as:
Mean · percent change
Percent Change From Baseline in Total Cholesterol (TC)
percent changePitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Percent Change From Baseline in Total Cholesterol (TC)-27.57 ± 10.359-28.92 ± 11.441-33.09 ± 10.732-32.99 ± 12.073
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)

percent change from baseline in high density lipoprotein-cholesterol (HDL-C)

Time frame:
Baseline to 12 weeks
Reported as:
Mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)
percent changePitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)4.28 ± 16.5013.42 ± 16.8204.93 ± 16.6292.63 ± 13.803
SecondaryTC:HDL-C Ratio

Ratio of mean total cholesterol to mean HDL-C at 12 weeks

Time frame:
12 weeks
Reported as:
Mean · ratio
TC:HDL-C Ratio
ratioPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
TC:HDL-C Ratio4.018 ± 1.12943.763 ± 0.86673.583 ± 1.09613.79 ± 1.2052
SecondaryTriglycerides (TG)

mean triglycerides at 12 weeks

Time frame:
12 weeks
Reported as:
Mean · mg/dL
Triglycerides (TG)
mg/dLPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Triglycerides (TG)132.4 ± 59.82122.2 ± 57.09124.4 ± 64.91122.6 ± 59.01
SecondaryNon-HDL:HDL Ratio

Ratio of non-HDL to HDL at 12 weeks

Time frame:
12 weeks
Reported as:
Mean
Non-HDL:HDL Ratio
MeasurePitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Non-HDL:HDL Ratio2.993 ± 1.09352.770 ± 0.88462.601 ± 1.09612.710 ± 1.1771
SecondaryApolipoprotein B (Apo B)

Apolipoprotein B at 12 weeks

Time frame:
12 weeks
Reported as:
Mean · mg/dL
Apolipoprotein B (Apo B)
mg/dLPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Apolipoprotein B (Apo B)114.5 ± 23.36111.1 ± 25.12102.3 ± 22.04102.4 ± 22.13
SecondaryApolipoprotein-A1 (Apo-A1)

Apolipoprotein-A1 at 12 weeks

Time frame:
12 weeks
Reported as:
Mean · mg/dL
Apolipoprotein-A1 (Apo-A1)
mg/dLPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Apolipoprotein-A1 (Apo-A1)164.6 ± 29.10166 ± 26.8166.9 ± 28.01160.9 ± 26.58
SecondaryApo-B:Apo-A1 Ratio

Ratio of Apo-B to Apo-A1 at 12 weeks

Time frame:
12 weeks
Reported as:
Mean · ratio
Apo-B:Apo-A1 Ratio
ratioPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Apo-B:Apo-A1 Ratio0.72 ± 0.2280.68 ± 0.1810.64 ± 0.1980.66 ± 0.205
SecondaryHigh Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks

high sensitivity C-reactive protein (hs-CRP) at 12 weeks

Time frame:
12 weeks
Reported as:
Mean · mg/L
High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks
mg/LPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks2.87 ± 5.1012.39 ± 3.0533.12 ± 5.1862.56 ± 2.958
SecondaryOxidized LDL at 12 Weeks

oxidized low density lipoprotein at 12 weeks

Time frame:
12 weeks
Reported as:
Mean · U/L
Oxidized LDL at 12 Weeks
U/LPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
Oxidized LDL at 12 Weeks59.93 ± 14.9658.59 ± 14.67954.32 ± 13.49654.70 ± 17.865
SecondaryNational Cholesterol Education Program [NCEP]LDL-C Target Attainment

Number of patients achieving NCEP LDL-C target (LDL-C less than or equal to 130 mg/dL)

Time frame:
up to 12 weeks
Reported as:
Number · Patients
National Cholesterol Education Program [NCEP]LDL-C Target Attainment
PatientsPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
National Cholesterol Education Program [NCEP]LDL-C Target Attainment1796723272

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 2 mg QD—3/316 (0.9%)22/316 (7%)
Atorvastatin 10 mg QD—1/102 (1%)6/102 (5.9%)
Pitavastatin 4 mg QD—1/300 (0.3%)17/300 (5.7%)
Atorvastatin 20 mg QD—2/103 (1.9%)4/103 (3.9%)
Most frequent serious events
Most frequent serious events
EventPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
angina unstableCardiac disorders0/3161/1020/3000/103
angina pectorisCardiac disorders0/3160/1020/3001/103
deafness neurosensoryEar and labyrinth disorders0/3160/1020/3001/103
encephalopathyNervous system disorders0/3160/1020/3001/103
myocardial infarctionCardiac disorders0/3160/1021/3000/103
pruritus generalizedSkin and subcutaneous tissue disorders1/3160/1020/3000/103
acute myocardial infarctionCardiac disorders1/3160/1020/3000/103
burning sensationNervous system disorders1/3160/1020/3000/103
abortion spontaneousPregnancy, puerperium and perinatal conditions1/3160/1020/3000/103
Most frequent other events
Most frequent other events
EventPitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QD
nasopharyngitisInfections and infestations10/3164/1028/3003/103
constipationGastrointestinal disorders7/3161/1023/3000/103
myalgiaMusculoskeletal and connective tissue disorders5/3161/1026/3001/103

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QDTotal
<=18 years00000
Between 18 and 65 years2197520773574
>=65 years97279330247
Age Continuous
Age Continuous(years)Pitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QDTotal
Mean58.4 ± 9.5159.2 ± 8.6357.9 ± 10.158.0 ± 9.1458.3 ± 9.58
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 2 mg QDAtorvastatin 10 mg QDPitavastatin 4 mg QDAtorvastatin 20 mg QDTotal
Female1745016455443
Male1425213648378
09

Study locations

192 sites
  • Y Forskning, Bispebjerg Hospital
    Copenhagen Nv, Denmark
  • Copenhagen University Hospital
    Copenhagen, Denmark
  • Medical Center
    Copenhagen, Denmark
  • Frederiks Hospital, Kardiologisk
    Frederiksberg, Denmark
  • Kolesterollaboratoriet
    Hellerup, Denmark
  • CCBR A/S
    Vejle, Denmark
  • Geri-Med Oy
    Helsinki, Finland
  • Kaisaniemen Laakariasema
    Helsinki, Finland
  • keravan Laakarikeskus
    Helsinki, Finland
  • SOK-tyoterveyshuolto
    Tampere, Finland
  • TYKS University Hospital
    Turku, Finland
  • Kardiologische Gemeinschaftspraxis Prof. Reifart
    Bad Soden/Taunus, Germany
  • Praxis Dr. Boenninghoff
    Beckum, Germany
  • Gemeinschaftspraxis am Bahnhof
    Berlin-Spandau, Germany
  • Klinische Forschung Berlin Mitte
    Berlin, Germany
  • Pharmakologisches Studienzentum Chemnitz
    Chemnitz, Germany
  • GWT-TUK mbH, Zentrum fur Klinische Studien
    Dresden, Germany
  • Internistische Diabetische Schwerpunktpraxis Dr.
    Frankfurt Am Main, Germany
  • Gemeinschaftspraxis Dr. Krause, Th. Menke
    Goch, Germany
  • Klinische Forschung Hamburg
    Hamburg, Germany
  • Innere Medizin I/Medizinische Klinik
    Heidelberg, Germany
  • Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl
    Lampertheim, Germany
  • ZET-Studien GmbH Leipzig
    Leipzig, Germany
  • Internistische Gemeinschaftspraxis
    Mainz, Germany
  • Praxis Dr. Wachter
    Mannheim, Germany
  • Gemeinschaftspraxis Melcherstaette
    Melcherstaette, Germany
  • Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
    Messkirch, Germany
  • Praxisgemeinschaft im Kleinen Biergrund
    Offenbach/M, Germany
  • Gemeinschaftspraxis Drs. Mockesch
    Weinheim, Germany
  • Intermed Institud Fur Klinische Forschung und Arzn
    Wiesbaden, Germany
  • Gemeinschaftspraxis Dr. Emden, Frank Drewes
    Worpswede, Germany
  • Apollo Hospital
    Andhra Pradesh, 500033, India
  • Care Hospital
    Andhra Pradesh, 500034, India
  • School of Diabetology, Nizam Institute of Medical Sciences
    Andhra Pradesh, 500082, India
  • Bhagwan Mahaveer Jain Heart Centre
    Bangalore, India
  • Sri Ramachandra Medical College Hospital
    Chennai, India
  • Heart Care Clinic
    Gujarat, 380054, India
  • Apollo Hospitals
    Hyderabaad, India
  • CARE Group of Hospitals
    Hyderabaad, India
  • St. John's Medical College Hospital,
    Karnataka, 560034, India
  • St. John's Medical College Hospital
    Karnataka, 560034, India
  • Bathia Hospital
    Maharashtra, 400007, India
  • LTMMC & General Hospital
    Maharashtra, 400022, India
  • Sir J. J. Group of Hospitals
    Maharashtra, 400027, India
  • King Edward Medical College & Hospital
    Maharashtra, 411001, India
  • Ruby Hall Clinic
    Maharashtra, 411001, India
  • Lokmanya Hospital
    Maharashtra, 411033, India
  • PD Hinduja Hospital
    Mumbai, India
  • Apollo Hospital
    New Delhi, 110044, India
  • Sir Gagaram Hospital
    New Delhi, 110060, India
  • Apollo Hospital
    Tamil Nadu, 600006, India
  • Department of Cardiology
    Tamil Nadu, 641004, India
  • Department of Internal Medicine, Soroka Medical Center
    Beersheva, Israel
  • Department of Internal Medicine A, Rambam Medical Center
    Haifa, Israel
  • Department of Internal Medicine, Wolfson Medical Center
    Holon, Israel
  • Center for Research, Hadassah University Hospital
    Jerusalem Ein Kerem, Israel
  • Meir Hospital
    Kfar Saba, Israel
  • Department of Medicine, Hadassah Medical Center
    Mount Scopus Jerusalem, Israel
  • Department of Internal Medicine, Rivka Sieff Medical Center
    Safed, Israel
  • Institute of Metabolic Diseases
    Tel Aviv, Israel
  • Institute of Lipid & Atherosclerosis Research
    Tel Hashomer, Israel
  • Dipartimento di Medicina Clinica e Biotecnologia Applicata
    Bologna, Italy
  • Centro di Ricerca Clinica
    Chieti, Italy
  • Gerontologia e Geriatria - Universita degli Studi
    Ferrara, Italy
  • Dipartimento di Medicina Interna DIMI
    Genova, Italy
  • Universita di Modena e Reggio Emilia, Policlinico
    Modena, Italy
  • Dipartimento di Medicina Clinica e Sperimentale
    Napoli, Italy
  • Medicina Clinica e delle Patologie Emergenti
    Palermo, Italy
  • Dipartimento di Medicina Interna e Scienze Biomediche
    Parma, Italy
  • U.O Malattie Metaboliche e Diabetologia
    Treviglio, Italy
  • Azienda Ospedaliero-Universitaria
    Trieste, Italy
  • Andromed Breda
    Breda, Netherlands
  • Middellaan 5
    Breda, Netherlands
  • Andromed Eindhoven
    Eindhoven, Netherlands
  • Bomanshof 8
    Eindhoven, Netherlands
  • Andromed Noord
    Groningen, Netherlands
  • Damsterdiep 9
    Groningen, Netherlands
  • Vasculair Onderzoek Centrum Hoorn
    Hoorn, Netherlands
  • Andromed Leiden
    Leiden, Netherlands
  • Doezastraat 1
    Leiden, Netherlands
  • Andromed Nijmegen
    Nijmegen, Netherlands
  • Kamerlingh Onnesstraat 16-18
    Nijmegen, Netherlands
  • Andromed Rotterdam
    Rotterdam, Netherlands
  • Mathenesserlaan 247
    Rotterdam, Netherlands
  • Albert Schweitzer Ziekenhuis
    Sliedrecht, Netherlands
  • Andromed Oost
    Velp, Netherlands
  • Reigerstraat 30
    Velp, Netherlands
  • Rivierenland Tiel
    Wp Tiel, Netherlands
  • Andromed Zoetermeer
    Zoetermeer, Netherlands
  • Parkdreef 142
    Zoetermeer, Netherlands
  • Volvat Medisinske Senter
    Fredrikstad, Norway
  • Nyomen Legekontor
    Kongsberg, Norway
  • Radhuset Spesialistsenter
    Oslo, Norway
  • Rikshospitalet - University Hospital
    Oslo, Norway
  • Skedsmo Medisinske Senter A.S.
    Skedsmokorset, Norway
  • Podlaski Osrodek Kardiologii
    Bialystok, Poland
  • NZOZ GCP Dobra Praktyka Lekaska
    Gruziadz, Poland
  • NZOZ Terapia Optima
    Katowice, Poland
  • NZOZ Esculap, Przychodnia Lekary Rodzinnych
    Losice, Poland
  • NZOZ Centrum, Poradnia Kardiologiczna
    Siedlce, Poland

Showing the first 100 of 192 sites across 13 countries. Choose a country and city above to see the rest.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2005
First posted
Nov 7, 2005
Start
Oct 2005
CompletionActual
Nov 2006
Results first posted
Dec 16, 2009
Last update
Jan 12, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00249249
First posted
Nov 7, 2005
Start date
Oct 2005
Completion
Nov 2006
Results posted
Dec 16, 2009
Last update
Jan 12, 2010

Study contacts

Dragos Budinski, Med Dr.
study director · Kowa Research Europe
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pitavastatin · Atorvastatin

Start the discussion